CTOs on the Move

Cellestis Limited

www.cellestis.com

 
Cellestis Limited is a Valencia, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.cellestis.com
  • 28358 Constellation Rd Ste 698
    Valencia, CA USA 91355
  • Phone: 661.775.7480

Executives

Name Title Contact Details

Similar Companies

northcoast medical

northcoast medical is a Morgan Hill, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

CerFlux

CerFlux Personalized Medicine aims to reduce the pain, reduce the discomfort, and reduce the cost of cancer treatment.

EMD Serono

EMD Serono is the North America biopharma business of Merck KGaA, Darmstadt, Germany, employing over 1,200 individuals around the country with U.S. headquarters located in Rockland, Massachusetts. The company develops and offers therapies for specialty-care conditions, like multiple sclerosis, infertility and cancer. EMD Serono is committed to transforming lives by developing therapies that patients need and providing industry-leading educational and support programs.

Crinetics

Crinetics Pharmaceuticals is a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company`s lead product candidate, paltusotine (formerly CRN00808), is an investigational, oral, selective nonpeptide somatostatin receptor type 2 biased agonist for the treatment of acromegaly, an orphan disease affecting more than 26,000 people in the United States. A Phase 3 program in acromegaly with paltusotine is underway. Crinetics also plans to advance paltusotine into a Phase 2 trial for the treatment of carcinoid syndrome associated with neuroendocrine tumors. The company is also developing CRN04777, an investigational, oral, nonpeptide somatostatin receptor type 5 (SST5) agonist for congenital hyperinsulinism, as well as CRN04894, an investigational, oral, nonpeptide ACTH antagonist for the treatment of Cushing`s disease, congenital adrenal hyperplasia and other diseases of excess ACTH. All of the company`s drug candidates are new chemical entities resulting from in-house drug discovery efforts and are wholly owned by the company.

ESSA Pharma

As a clinical-stage pharmaceutical company founded on cutting-edge research, ESSA is focused on developing novel therapeutics for cancer patients. ESSA embraces innovation not only in our products but also in our approach. We re firmly rooted in creative and open thinking, giving us an energy and approach that makes us a different kind of pharmaceutical company.